Conference call to begin at 4:30 p.m. ET

Read more here:
Vaxart to Host Third Quarter 2022 Business Update and Financial Results Conference Call on November 8

SANTA CLARA, Calif., Oct. 20, 2022 (GLOBE NEWSWIRE) -- Shockwave Medical, Inc. (NASDAQ: SWAV), a pioneer in the development of Intravascular Lithotripsy (IVL) to treat complex calcified cardiovascular disease, will report financial results for the third quarter 2022 after market close on Monday, November 7, 2022. Company management will host a corresponding conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time.

Read the original here:
Shockwave Medical Announces Details for Conference Call Discussing Third Quarter 2022 Results

BERKELEY HEIGHTS, N.J., Oct. 20, 2022 (GLOBE NEWSWIRE) -- CorMedix Inc. (Nasdaq: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of life-threatening conditions and diseases, today announced that an abstract has been accepted for presentation at the American Society of Nephrology (ASN) annual meeting being held in Orlando, Florida, November 3 – 6.

Read this article:
CorMedix Inc. Announces Abstract Presentation at Upcoming American Society of Nephrology Conference

Stephen Simes career public biotech company CEO and Ryan Dunlap CFO with public biotech company experience join Board

The rest is here:
CytoDyn Announces Appointment of Additional Directors with Industry Experience

LEXINGTON, Mass., Oct. 20, 2022 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO), a leader in the rapid detection of sepsis-causing pathogens and antibiotic resistance genes, announced today that it has initiated studies to expand the number of pathogens detected on the FDA-cleared T2Bacteria® Panel to include the detection of Acinetobacter baumannii.

Read the original here:
T2 Biosystems Initiates Studies to Add Acinetobacter Baumannii to the FDA-Cleared T2Bacteria Panel

Revenue on September 30, 2022

Follow this link:
Guerbet: Revenue at September 30, 2022

WOBURN, Mass., Oct. 20, 2022 (GLOBE NEWSWIRE) -- Biofrontera Inc. (Nasdaq: BFRI), a biopharmaceutical company specializing in the commercialization of dermatological products, announced today that Erica Monaco, Chief Executive Officer, will be presenting and meeting with registered investors at the LD Micro Main Event XV that will be held October 25-27, 2022 at the Luxe Sunset Boulevard Hotel in Southern California.

Continued here:
Biofrontera Inc. to Present at the LD Micro Main Event XV Investor Conference

DEINOVE (Euronext Growth Paris: ALDEI), a French biotech company, pioneer in the exploration and exploitation of bacterial biodiversity to address the urgent, global challenge of antibiotic resistance, informs its shareholders that the Extraordinary General Meeting (AGE) held on October 17, 2022 has followed the recommendations of the Board of Directors, and adopted all the resolutions that the Board was favorable to, i.e. 10 out of the 11 resolutions.

Continue reading here:
DEINOVE - Adoption of the resolutions at the Shareholders’ Extraordinary General Meeting on October 17, 2022

Idorsia will publish its financial results for the first nine months of 2022 on October 25, 2022, at 07:00 CEST.

Continue reading here:
Invitation to Idorsia's nine-month financial results 2022 webcast and conference call

REDWOOD CITY, Calif., Oct. 20, 2022 (GLOBE NEWSWIRE) -- Codexis, Inc. (Nasdaq: CDXS), a leading enzyme engineering company enabling the promise of synthetic biology, today announced that it will report its financial results for the third quarter of 2022 on Thursday, November 3, 2022, following the close of market. Codexis management will host a conference call and webcast at 4:30 p.m. Eastern Time to discuss the Company’s financial results and provide a business update.

Originally posted here:
Codexis to Report Third Quarter 2022 Financial Results on November 3

Awarded $17.6 million Product Development Research grant by the Cancer Prevention & Research Institute of Texas (CPRIT) to fund 186RNL development for leptomeningeal metastases (LM)

Continued here:
Plus Therapeutics Reports Third Quarter 2022 Financial Results and Business Highlights

Call scheduled for Tuesday, November 8?? at 4:30 pm Eastern Time Call scheduled for Tuesday, November 8?? at 4:30 pm Eastern Time

View post:
Beyond Air® Schedules Second Fiscal Quarter 2023 Financial Results Conference Call and Webcast

See the original post:
Amarin Appoints Adam Berger and Geraldine Murphy to Board of Directors

Monthly information regarding the total number of voting rights and

Read the rest here:
Monthly information regarding the total number of voting rights and total number of shares of the Company as of September 30, 2022

EDISON, N.J., Oct. 20, 2022 (GLOBE NEWSWIRE) -- Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA), a clinical stage biopharmaceutical company focused on Artificial Intelligence (“AI”)-driven therapeutic drug development for the treatment of non-alcoholic steatohepatitis (“NASH”), hepatocellular carcinoma (“HCC”), and other fibrotic diseases, today announced that the peer-reviewed journal, Clinical Pharmacology in Drug Development, has published the results of a clinical trial examining the effect of food on the oral bioavailability of rencofilstat, the Company’s lead drug candidate.

Read the original here:
Hepion Pharmaceuticals Announces Publication of Food Effect Study with Rencofilstat

SAN DIEGO, Oct. 20, 2022 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced it will report third quarter 2022 financial results on Thursday, October 27, 2022, after the close of the U.S. financial markets. The Company will host a conference call and webcast to discuss the financial results and provide a general business update at 4:30 p.m. ET.

View original post here:
Travere Therapeutics to Report Third Quarter 2022 Financial Results

- Two preclinical posters highlighting the JTX-1484 program and LILRB family at SITC 2022 -

Read more:
Jounce Therapeutics to Present Multiple Posters at the Society for Immunotherapy of Cancer’s (SITC) 37th Annual Meeting and the European Society of...

– New and Updated Preclinical Data Highlight Potential of GSPT1-directed Molecular Glue Degrader (MGD) MRT-2359 in the Treatment of MYC-driven Cancers –

View post:
Monte Rosa Therapeutics to Present at 5th Annual Targeted Protein Degradation Summit and 34th EORTC-NCI-AACR Symposium

Ridinilazole resulted in a 53% relative risk reduction in recurrence of C. difficile infection compared to treatment with vancomycin

Here is the original post:
Summit Therapeutics Presents Ri-CoDIFy Trial Results for Microbiome-Sparing Ridinilazole at IDWeek 2022

REGULATED INFORMATION

Read more here:
Bone Therapeutics provides Third Quarter 2022 Business Update